申请人:GLACTONE PHARMA DEVELOPMENT AB
公开号:US10781197B2
公开(公告)日:2020-09-22
Disclosed are sulfonamide analogues of galiellactone of formula (I) as STAT3-inhibitors for use in the treatment of a STAT3 signaling related disorder, e.g. solid cancers, hematological cancers, benign tumors, hyperproliferative diseases, inflammations, autoimmune diseases, graft or transplant rejections, delayed physiological function of grafts or transplants, neurodegenerative diseases and viral infections. The sulfonamide comprises a cyclic substituent.
本发明公开了作为 STAT3 抑制剂的式(I)的镓内酯磺酰胺类似物,用于治疗 STAT3 信号转导相关疾病,如实体癌、血液肿瘤、良性肿瘤、过度增殖性疾病、炎症、自身免疫性疾病、移植物或移植排斥、移植物或移植的生理功能延迟、神经退行性疾病和病毒感染。磺酰胺包括一个环状取代基。